Davenport & Co’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-5,063
| Closed | -$439K | – | 1033 |
|
|
2023
Q2 | $439K | Buy |
5,063
+306
| +6% | +$26.5K | ﹤0.01% | 759 |
|
|
2023
Q1 | $463K | Sell |
4,757
-1,700
| -26% | -$165K | ﹤0.01% | 724 |
|
|
2022
Q4 | $668K | Buy |
6,457
+305
| +5% | +$31.6K | 0.01% | 593 |
|
|
2022
Q3 | $522K | Sell |
6,152
-438
| -7% | -$37.2K | ﹤0.01% | 648 |
|
|
2022
Q2 | $546K | Buy |
6,590
+444
| +7% | +$36.8K | ﹤0.01% | 650 |
|
|
2022
Q1 | $474K | Buy |
6,146
+271
| +5% | +$20.9K | ﹤0.01% | 734 |
|
|
2021
Q4 | $519K | Buy |
+5,875
| New | +$519K | ﹤0.01% | 725 |
|
|
2021
Q1 | – | Sell |
-5,044
| Closed | -$442K | – | 806 |
|
|
2020
Q4 | $442K | Sell |
5,044
-85
| -2% | -$7.45K | ﹤0.01% | 557 |
|
|
2020
Q3 | $390K | Sell |
5,129
-1,141
| -18% | -$86.8K | ﹤0.01% | 518 |
|
|
2020
Q2 | $773K | Buy |
6,270
+132
| +2% | +$16.3K | 0.01% | 370 |
|
|
2020
Q1 | $519K | Buy |
6,138
+910
| +17% | +$76.9K | 0.01% | 400 |
|
|
2019
Q4 | $442K | Sell |
5,228
-1,549
| -23% | -$131K | ﹤0.01% | 497 |
|
|
2019
Q3 | $580K | Sell |
6,777
-150
| -2% | -$12.8K | 0.01% | 418 |
|
|
2019
Q2 | $593K | Buy |
6,927
+1,952
| +39% | +$167K | 0.01% | 414 |
|
|
2019
Q1 | $442K | Buy |
4,975
+47
| +1% | +$4.18K | 0.01% | 445 |
|
|
2018
Q4 | $420K | Sell |
4,928
-3,620
| -42% | -$309K | 0.01% | 435 |
|
|
2018
Q3 | $829K | Buy |
8,548
+190
| +2% | +$18.4K | 0.01% | 347 |
|
|
2018
Q2 | $787K | Buy |
8,358
+392
| +5% | +$36.9K | 0.01% | 356 |
|
|
2018
Q1 | $646K | Buy |
7,966
+4,382
| +122% | +$355K | 0.01% | 393 |
|
|
2017
Q4 | $320K | Buy |
+3,584
| New | +$320K | ﹤0.01% | 540 |
|